home / stock / sprb / sprb news


SPRB News and Press, Spruce Biosciences Inc.

Stock Information

Company Name: Spruce Biosciences Inc.
Stock Symbol: SPRB
Market: NASDAQ
Website: sprucebiosciences.com

Menu

SPRB SPRB Quote SPRB Short SPRB News SPRB Articles SPRB Message Board
Get SPRB Alerts

News, Short Squeeze, Breakout and More Instantly...

SPRB - Buy Recommendation Issued On SPRB By H.C. Wainwright

2026-02-19 06:15:30 ET H.C. Wainwright analyst issues BUY recommendation for SPRB on February 19, 2026 11:07AM ET. The previous analyst recommendation was Buy. SPRB was trading at $53.48 at issue of the analyst recommendation. The overall analyst consensus : HOLD. Cu...

SPRB - Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)

Based on FDA Feedback, Company Continues to Advance BLA Submission for TA-ERT Using CSF HS-NRE as Reasonably Likely Surrogate Endpoint for Accelerated Approval BLA Submission for TA-ERT is Now Anticipated in the Fourth Quarter to Accommodate Drug Product PPQ Requirement Spru...

SPRB - Spruce Biosciences to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will participa...

SPRB - Long-Term Data Presented at the 22nd Annual WORLDSymposium(TM) Highlights Tralesinidase Alfa Enzyme Replacement Therapy's Potential as the First Disease-Modifying Treatment Option for Sanfilippo Syndrome Type B (MPS IIIB)

Treatment with Weekly TA-ERT Demonstrated Rapid and Durable Normalization of Cerebral Spinal Fluid Heparan Sulfate Non-Reducing End (CSF HS-NRE), a Surrogate Endpoint Reasonably Likely to Predict Clinical Benefit TA-ERT Treatment Stabilized and Preserved Cognitive and Non-Cognitive Outcom...

SPRB - Spruce Biosciences Adds Regulatory and Clinical Development Expertise to Leadership Team

Daven Mody, Pharm.D., Appointed as Senior Vice President, Regulatory and Quality Bruno Gagnon, B.Pharm., M.Sc., Appointed as Senior Vice President, Clinical Development Operations Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused o...

SPRB - Spruce Biosciences Announces Data Presentations at the 22nd Annual WORLDSymposium(TM)

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that data on the long-term administration of its tralesinidase alfa enzyme re...

SPRB - Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration

Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration PR Newswire CAMBRIDGE, Mass. , ROTTERDAM, Netherlands and SHANGHAI , Jan. 18, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to...

SPRB - Spruce Biosciences Secures Up to $50 Million in Growth Capital from Avenue Capital

Initial Funding of $15 Million from the First of Four Tranches, Extending Cash Runway into 2027 Facility Will Support Advancement and Potential Launch of TA-ERT for the Treatment of MPS IIIB Spruce Biosciences, Inc. (Spruce) (Nasdaq: SPRB), a late-stage biopharmaceutical compa...

SPRB - Spruce Biosciences Appoints Proven Pharmaceutical Commercial Leader Keli Walbert to Board of Directors

Keli Walbert brings decades of commercial leadership experience and a proven track record of successful product launches in rare disease Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurol...

SPRB - SPRB Price Target Alert: $259.00. Issued by JMP Securities

2025-11-11 07:07:19 ET from JMP Securities issued a price target of $259.00 for SPRB on 2025-11-11 10:52:57. The adjusted price target was set to $259.00. At the time of the announcement, SPRB was trading at $115.61. The overall price target consensus is at $207.00 with ...

Next 10